Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.

Scientific reports - 1 Dec 2017

Pintarelli Giulia, Galvan Antonella, Pozzi Paolo, Noci Sara, Pasetti Giovanna, Sala Francesca, Pastorino Ugo, Boffi Roberto, Colombo Francesca

Abstract excerpt

Smoking-cessation therapy reduces the risk of smoking-related diseases, but is successful only in a fraction of smokers. There is growing evidence that genetic variations in nicotinic acetylcholine receptor (nAChR) subunits influence the risk of nicotine dependence and the ability to quit smoking. To investigate the role of polymorphisms in nAChR genes on smoking quantity and the outcome of smoking-cessation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 5' Untranslated Regions
Share to Bupropion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbon Monoxide

Share to Exhalation

Share to Pharmacogenomic Variants

Share to Receptors, Nicotinic

Share to Smoking

Share to Tobacco Use Disorder

Source

Open in PubMed Open full text

Identifiers

PMID: 29196725
DOI: 10.1038/s41598-017-16946-6
PMCID: PMC5711795

Genes

CHRNA5
CPD
CHRNA4
CHRNB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic study of seven polymorphisms in three nicotinic acetylcholine receptor subunits in smoking-cessation therapies.PMID 29196725Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy.Semantic proximity Read ↗

A systematic review of genetic variation within nicotinic acetylcholine receptor genes and cigarette smoking cessation.Semantic proximity Read ↗

Cholinergic receptor nicotinic alpha 5 subunit polymorphisms are associated with smoking cessation success in women.Semantic proximity Read ↗

Impact of genetic variability in nicotinic acetylcholine receptors on nicotine addiction and smoking cessation treatment.Semantic proximity Read ↗

The Role of Pharmacogenetics in Smoking.Semantic proximity Read ↗

Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo‐Controlled TrialSemantic proximity Read ↗

Pharmacogenetics of smoking cessation therapySemantic proximity Read ↗

Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.Semantic proximity Read ↗

Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Semantic proximity Read ↗

Genetic Variants in Smoking-Related Genes in Two Smoking Cessation Programs: A Cross-Sectional Study.Semantic proximity Read ↗

Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.